CROS NT Group to Attend Third Annual Oncology Clinical Trials

Online, November 23, 2010 (Newswire.com) - The German subsidiary of the CROS NT Group, CROS DE GmbH, will be present at the Third Annual Oncology Clinical Trials in Munich, Germany from 29 November through 1 December. The therapeutic area of oncology is one of CROS NT's areas of excellence regarding clinical trial experience, and the CROS DE management team is at the forefront of clinical trial consultancy in this field. CROS NT's involvement in oncology clinical trials, including project management, statistics and data management, has resulted in over 10,000 patients involved in Phase I-IV clinical trials across multiple indications.

Thomas Zwingers, Medical Scientific Director for CROS DE, will be attending the event and brings over 20 years of experience working in clinical trials. Zwingers is the oncology clinical trial specialist for the CROS NT Group. Also attending the event from CROS DE will be Frank Freischläger, Vice President, and Gudrun Skiba, Business Development Manager.

With oncology being one of the fastest growing therapeutic areas in the pharmaceutical industry in terms of market size, the Clinical Trials event will focus on "innovative approaches to overcoming the practical challenges of clinical trials in oncology". The Clinical Trials in Oncology will be attended by leading pharmaceutical and biotechnology companies who will give case study presentations and lead panel and roundtable discussions. The event will particularly focus on innovative technologies during Phase I-III and strategies to expedite and improve efficiency during trial setup. For more information on the Third Annual Oncology Clinical Trials, visit http://www.clinicaltrialsevents.com/oncology/index.html.